Atypic hand and foot syndrome due to capecitabine therapy: A case report

Year 2008, Volume: 23 Issue: 3, 140 - 141, 01.04.2008

Eylem Karatay Erdem Akbal Dicle Koca Gülsüm Gönülalan Mustafa Altınbaş

Abstract

Hand-foot syndrome, also known as palmar-plantar dysesthesia, is a drug reaction characterized by dysesthesia, erythema, and edema desquamation in the palms of the hands and soles of the feet. Cytarabine, docetaxel, ARA-C, capecitabine and 5-FU are the drugs related with hand-foot syndrome. In our case, erythema and edema desquamation developed on the dorsal area of the hand and wrist after capecitabine treatment. The lesion is reported because its location is rare and it has not been reported before.

Keywords

capecitabine, Middle Aged, Female, Adverse effects, Drug Toxicity, Syndrome, Hand, Foot, Paresthesia, Erythema, Keratolytic Agents

Kapesitabin tedavisi alan hastada gelişen atipik el ayak sendromu: Olgu sunumu

Abstract

Palmar-plantar eritrodizestezi sendromu olarak da bilinen el ayak sendromu, çeşitli kemoterapik ajanların kullanımı sonrasında gelişen bir ilaç reaksiyonudur. Palmar-plantar bölgelerde çeşitli derecelerde dizestezi, eritem ve ödemle beraber deskuamasyon izlenir. Dosetaksel, Ara-C, kapesitabin ve 5 FU başlıca sorumlu ajanlardır. Olgumuzda kapesitabin tedavisi sonrası el üstü ve el bileğinde eritem, ödem, deskuamasyon gelişti. Lezyonun lokalizasyon yerinin nadir olması ve litatürde daha önce bildirilmemesi nedeni ile sunuldu.

Keywords

El ayak sendromu, kapesitabin

References

• 1. Elasmar SA, Saad ED, Hoff PM. Case report: handfoot syndrome induced by the oral fluoropyrimidine S-1. Jpn J Clin Oncol 2001;31(4):172-4.
• 2. Budman DR. Capecitabine. Invest New Drugs 2000;18(4):355-63.
• 3. Chen GY, Chen YH, Hsu MM, Tsao CJ, Chen WC. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol 2001;145(3):521-2.
• 4. Gerbrecht BM. Current Canadian experience with capecitabine: partnering with patients to optimize therapy. Cancer Nurs 2003;26(2):161-7.
• 5. Liu X, Song S, Guan Z, Wu S, Duan Y, Yu J, Yang L. Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer. [Article in Chinese] Zhonghua Zhong Liu Za Zhi 2002;24(1):71-3. [Abstract]
• 6. Nishida M. Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine. Nippon Yakurigaku Zasshi 2003;122(6):549-53.
• 7. S m o r e n b u rg CH, Bontenbal M, Verweij J. Capecitabine in breast cancer: current status. Clin Breast Cancer 2001;1(4):288-93. [Abstract]
• 8. Vivier A. Atlas of clinical dermatology. 3rd ed., Spain: Elsevier Science Limited; 2002. p. 405-11.
• 9. Risum S, Langer SW. Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment. [Article in Danish] Ugeskr Laeger 2003;165(33):3161-2. [Abstract]
• 10. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002;16(12 Suppl No 14):31-7.
• 11. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002;20(1):3-10.
• 12. Maino KL, Norwood C, Stashower ME. Onycholysis with the appearance of a “s u n s e t” secondary to capecitabine. Cutis 2003;72(3):234-6.